Rossari Biotech Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹685Cr
- +18.1% YoY
- +17.7% QoQ
- Net profit
- ₹46Cr
- +35.3% YoY
- +39.4% QoQ
- Margin
- 11%
- −1 pp YoY
- −1 pp QoQ
Guidance rank: #45 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
Rossari Biotech Q4 FY26 key numbers
- Revenue
- CAPEX of Rs. 50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments.
As stated in Rossari Biotech's Q4 FY26 earnings call transcript · published 24 Aug 2026. Reported figures, not investment advice.
The short version
Targeting a minimum 15% growth in FY27 driven by expansions in agro, pharma, personal care, and textile exports (including markets like Bangladesh, Thailand, Turkey, and Brazil). The company expects a minimum of 15% revenue growth in FY27 driven by expansion in personal care, agro, textile exports, and animal health and nutrition (AHN) segments.
From Rossari Biotech's Q4 FY26 earnings-call transcript · updated 24 Aug 2026.
Revenue & Sales Performance
- Targeting a minimum 15% growth in FY27 driven by expansions in agro, pharma, personal care, and textile exports (including markets like Bangladesh, Thailand, Turkey, and Brazil).
- New premix facility in Animal Health Nutrition (AHN) expected to ramp up revenues starting FY27, supporting growth.
- CAPEX of Rs. 50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments.
- Growth expected over the next 2-3 years through new customer additions and expansion in high-margin segments such as pharma, oil and gas, aroma, personal care, food processing, and institutional chemicals.
- Core B2B businesses to drive growth with latent growth in Agro, Textile, AHN, and Personal Care.
2 more points from Rossari Biotech's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Rossari Biotech said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY27 CAPEX plan is Rs. 50 crore to Rs. 75 crore, including:
- New pharma facility expansion
- Aroma chemical facility expansion
- Earlier large CAPEX plans (Rs. 190 crore across multiple sites) have been rephased due to market conditions; some parts postponed to optimize cash flow and returns
- New R&D facility set up in Navi Mumbai consolidating existing operations, supporting faster innovation and scale-up
- Ethoxylation capacity expanded to 66,000 metric tons per annum at Dahej, improving supply reliability
- Ongoing focus on capacity utilization and operational efficiencies to support growth
2 more points from Rossari Biotech's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rossari Biotech said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Rossari Biotech's call on order book
Create a free account to keep reading this call
Rossari Biotech — Quarterly revenue & net profit
Rossari Biotech Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 685 | 580 | +18.1% | 582 | +17.7% |
| Operating profit (EBITDA) | 77 | 69 | +11.6% | 69 | +11.6% |
| Operating margin | 11% | 12% | -1 pp | 12% | -1 pp |
| Profit before tax | 64 | 48 | +33.3% | 43 | +48.8% |
| Net profit (PAT) | 46 | 34 | +35.3% | 33 | +39.4% |
| EPS (₹) | 8.30 | 6.22 | +33.4% | 5.92 | +40.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹698 Cr, net profit ₹39 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rossari Biotech's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Indian Phosphate (Q4 FY26)
H2 FY26 Revenue (Consolidated):** ₹580.25 Cr, up from ₹451.59 Cr in H2 FY25 — a year-on-year increase of ₹128.66 Cr. Key investor presentation takeaways from In
- Paragon Fine (Q4 FY26)
Revenue for H2FY26:** Rs 68.88 Cr, up 7.41% YoY from Rs 64.13 Cr in H2FY25 (Page 22). Key investor presentation takeaways from Paragon Fine's Q4 FY26 investor p
- IVP (Q4 FY26)
Q4 FY26 revenue from operations: ₹164.44 crore . Key investor presentation takeaways from IVP's Q4 FY26 investor presentation — and how it ranks against sector
- Vishnu Chemicals (Q4 FY26)
Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rossari Biotech and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rossari Biotech Q4 FY26 results?
Targeting a minimum 15% growth in FY27 driven by expansions in agro, pharma, personal care, and textile exports (including markets like Bangladesh, Thailand, Turkey, and Brazil). The company expects a minimum of 15% revenue growth in FY27 driven by expansion in personal care, agro, textile exports, and animal health and nutrition (AHN) segments.
What is Rossari Biotech share price analysis?
Rossari Biotech currently shows a neutral. The stock trades at a P/E of 18.4 with a market cap of ₹2,779 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rossari Biotech planning capital expenditure?
FY27 CAPEX plan is Rs. 50 crore to Rs. 75 crore, including:.
Keep Rossari Biotech on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
